Could this be the best ASX healthcare stock in 2020?

The Polynovo Limited (ASX: PNV) share price is up over 300% in just 12 months. But this could still be just the beginning of its growth story.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in ASX healthcare company Polynovo Limited (ASX: PNV) have been on a tear recently. Since the beginning of this year, Polynovo's share price has surged over 55% to $3.07 as at the time of writing.

But the charge really began a lot earlier than 2020: longer-term shareholders who have held Polynovo for at least 12 months are now sitting on gains of well over 300%.

Why is Polynovo's share price skyrocketing?

Polynovo is a junior healthcare company which specialises in the development of biodegradable medical devices to aid in tissue repair. Its flagship medical technology is called NovoSorb, which was originally developed by the CSIRO. It is a medical grade polymer designed for use in surgery, tissue repair, and other medical procedures and will safely biodegrade and be excreted by the body.

Novosorb BTM is the first fully commercialised Novosorb product developed by Polynovo. It is a synthetic polymer matrix that clinicians can use to treat serious burn victims. The polymer can be applied to burns and trauma sites on the body and will encourage the construction of new skin tissue, before being eventually absorbed and excreted, leaving only biological material behind.

The reason behind Polynovo's share price growth is the underlying momentum of the company. The last couple of months have been very strong for Polynovo. In early January it announced that December was the first month in which it had generated more than $2 million in sales. And while CEO Paul Brennan warned that sales could continue to be "lumpy", it was still a significant milestone for Polynovo, especially considering that the first time the company had generated $1 million in sales in a single month was as recently as April 2019.

Sales growth could continue to accelerate throughout 2020 as Novosorb breaks into new overseas markets.

Soon after, Polynovo also announced that Novosorb BTM had been used in surgical operations in the UK, Germany and Switzerland, and that orders had also been placed for the product in Austria.

Plus, Polynovo has already entered the US market. In a recent interview with Alan Kohler, Paul Brennan stated that Polynovo was supplying various hospitals in the US, and last year the company announced it had been granted access to the US Department of Defence.

In the same interview with Alan Kohler, Paul Brennan laid out his aggressive growth strategy, which should please long-term investors. Although Brennan confirmed that Polynovo had delivered a number of profitable months recently, he stated he was more inclined to invest that money back into the business rather than necessarily announce an overall profit for the half year.

While this strategy might turn off short-term investors seeking an earnings surprise from Polynovo's half-year results announcement (which is due at the end of the month), it should reassure shareholders that management has the longer-term goals of the company in mind when making business decisions.

Foolish Takeaway

Along with other junior healthcare companies like Paradigm Biopharmaceuticals Limited (ASX: PAR), Medical Developments International Limited (ASX: MVP) and Opthea Limited (ASX: OPT), Polynovo is an exciting investment prospect. It has already commercialised its biotechnology, is expanding globally and is pursuing an aggressive growth strategy.

This isn't to say it isn't risky. It is still a young company with a short track record, and there is always the chance its technology will be superseded by something else. It should also be noted that a few uses of its product in Germany and Switzerland doesn't necessarily mean it will be adopted by hospitals all across Europe.

But for those investors wishing to take some degree of risk and back a growing healthcare company, Polynovo makes for an attractive investment. Novosorb is an exciting technology with potentially wide medical applications, and its growth story is difficult to ignore.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Rhys Brock owns shares of Medical Developments International Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

ASX 200 shares broker downgrade origami paper fortune teller with buy hold sell and dollar sign options
Broker Notes

Are Bendigo Bank shares a buy, hold or sell? Here's Macquarie's latest recommendation

Should I buy the dip on Bendigo Bank shares today?

Read more »

Happy man working on his laptop.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Rising share price chart.
Share Gainers

Why Canyon Resources, Nufarm, Paladin Energy, and WiseTech shares are charging higher today

These shares are starting the week on a positive note. But why?

Read more »

A worried man holds his head and look at his computer.
Share Fallers

Why Elders, James Hardie, Origin Energy, and SGH shares are falling today

These shares are starting the week in the red. But why?

Read more »

Man with rocket wings which have flames coming out of them.
Gold

Guess which ASX gold stock just rocketed 167% on big news!

Investors are sending the ASX gold stock flying higher on Monday. Let’s find out why.

Read more »

The words short selling in red against a black background
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

The last piece of the jigsaw being fitted, indicating good news for a share price on merger or acquisition
Mergers & Acquisitions

WiseTech share price storms higher on $3.25b blockbuster acquisition

What is the company spending billions on? Let's find out.

Read more »